XORTX Adds Late Stage Gout Program to Pipeline
XORTX to focus on late stage allopurinol intolerant gout program; discussion with FDA planned for first half 2025 regarding ...
kr-asia7d
The decade-long wait ends: A breakthrough in gout treatment
New treatments like dotinurad provide safer, more effective solutions for millions battling gout and hyperuricemia.
Financial Post11d
XORTX Adds Late Stage Gout Program to Pipeline
This decline in Febuxostat use has created an opportunity for a novel XOI to address the underlying unmet medical need which the XRx-026 program aims to fill. XORTX is a pharmaceutical company with ...
Morningstar11d
XORTX Adds Late Stage Gout Program to Pipeline
This decline in Febuxostat use has created an opportunity for a novel XOI to address the underlying unmet medical need which the XRx-026 program aims to fill. About XORTX Therapeutics Inc. XORTX ...
Stockhouse11d
XORTX Adds Late Stage Gout Program to Pipeline
This decline in Febuxostat use has created an opportunity for a novel XOI to address the underlying unmet medical need which the XRx-026 program aims to fill. About XORTX Therapeutics Inc. XORTX is a ...
Medscape6d
Febuxostat for Treatment of Chronic Gout
[30,31,37,38] There do not appear to be any significant advantages in the use of febuxostat over allopurinol in patients who already experience adequately lowered serum uric acid levels with ...